Louis Lombardo is a Partner in MSF’s Corporate Department. Mr. Lombardo provides corporate and securities law advice to clients in mergers and acquisitions, public and private securities offering and other transactional matters across a variety of industries, including technology, media, life sciences and consumer products. Mr. Lombardo regularly represents senior management, corporate boards, strategic market participants and investment funds with respect to corporate governance issues, mergers, acquisitions, dispositions, joint ventures and other complex business transactions, as well as public and private issuers and investors in equity and debt financing transactions. Mr. Lombardo also has extensive experience representing clients in life science transactional matters including licensing, development collaborations, co-promotion arrangements, asset acquisition and disposition and financing.
Brooklyn Law School. J.D.
Wagner College. B.S
State of New York
State of New Jersey
Before joining MSF in 2016, Mr. Lombardo was a principal of Lombardo Dufresne LLP, a boutique corporate transactional law firm that he co-founded in 2006, and served as Senior Vice President and Deputy General Counsel to a Kadmon Holdings Inc., which he helped found in 2009. Prior to 2006, Mr. Lombardo was Counsel in the Corporate and Finance Group of Kaye Scholer LLP (now Arnold & Porter Kaye Scholer LLP), New York, New York.
Represented a New York-based publicly traded biotechnology company in a public re-offer of securities by selling stockholders.
Represented the placement agent in a registered direct offering of preferred stock of a New Jersey-based, publicly traded biotechnology company.
Represented a New York-based biotech company in its worldwide license of a clinical stage small molecule and all of the related intellectual property from a New York-based biotech investment fund.
Represented a venture capital fund in multiple investments into early stage biotechnology companies.
Represented a Pittsburgh-based pharmaceutical company in a co-promotion arrangement with a major publicly traded pharmaceutical company for a branded generic product for the treatment of Wilson’s disease.
Represented a New York-based private company in its acquisition of a Pennsylvania-based pharmaceutical company.
Represented a New York-based importing company in its divestiture of a premier vodka brand.
Represented the shareholders in their divestiture of a New Jersey-based access systems integrator.
Represented a New York based private equity fund in its acquisition of a New Jersey-based musical instrument rental company.
Represented a New-York-based technology company in its senior credit facility.
Represented a Florida-based publicly traded company in its acquisition of low power TV stations from Viacom.
Represented a New York-based risk management software company in its merger with a major, privately-held data software company.
Represented a New York-based biotech company in connection with its senior credit facility and senior convertible credit facility with a syndicate of private lenders.
Represented a New York-based private real estate fund in connection with its senior credit facility with national banking institution.